Research article · 2016
Conference abstract
Mousemodel for testing anti-Dux4 therapies for FSHD
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
(FSHD) patients typically suffer from asymmetric muscle loss with age and the disease is associated with genomic alterations that lead to dominant expression of the toxic DUX4 protein. To generate an animal model to study the effects of DUX4, a doxycycline-inducible transgene encoding DUX4 and 3? genomic DNA was introduced into a euchromatic region of the mouse X chromosome. Surprisingly, without induction, DUX4 RNA was expressed at low levels in many tissues and animals displayed a variety of unexpected dominant leaky phenotypes, including male-specific lethality. Occasional live-born males were expressed DUX4 RNA at low levels but did not show signs of dystrophy before they died by 4-6 weeks of age. To study the effects of DUX4 expression on muscle regeneration, this lethality was bypassed by isolating and transplanting iDUX4 satellite cells from iDUX4 males. In the presence of doxycycline, it was observed a dose-dependent suppression of new fiber formation by transplanted satellite cells. Data on the use of this conditional model to test anti-DUX4 therapeutics, specifically gene therapy targeting the DUX4 message in transplanted satellite cells will be presented. This approach, using the first transgenic mouse model to show pathologies due to FSHD-related D4Z4 sequences, allows quantitative testing of therapies for FSHD directed against DUX4. PDF HTML
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 13 Aug 2012
Role of DUX4 and Pax3/7 interferences in facioscapulohumeral muscular dystrophy (FSHD) pathogenesis
Research article · 25 Oct 2015
Precision Cut Cancer Tissue Slices in Anti-Cancer Drug Testing
Editorial · 4 Dec 2017
HIV resistance to anti-retroviral therapy in sub-Saharan Africa: Is it time for individualized treatment to succeed test and treat strategy?
Conference abstract · 1 Sep 2015
The 2013 ASCO/CAP recommendations on HER2 testing in breast cancer have increased equivocal HER2 FISH results and the use of anti-HER2 therapies
More from this journal
The newest in Journal of Stem Cell Research & Therapy.
Article · 2 Jun 2026
Stem Cell Therapy for Diabetes Mellitus: Exploring Cellular Approaches for Pancreatic Regeneration
Article · 2 Jun 2026
Stem Cell Banking and Preservation: Advancing Future Therapeutic Possibilities through Cellular Storage
Article · 2 Jun 2026
Stem Cells in Cardiovascular Regeneration: Emerging Strategies for Heart Repair and Functional Recovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Stem Cell Research & Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Abhijit Dandapat”
- BylineArticles whose byline prints “Robert Arpke”
- BylineArticles whose byline prints “Darko Bosnakovski”
- BylineArticles whose byline prints “Lynn Hartweck”
- BylineArticles whose byline prints “Kristen A Baltgalvis”
- BylineArticles whose byline prints “Derek Vang”
- BylineArticles whose byline prints “Megan Roth”
- BylineArticles whose byline prints “June Baik”

